Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells

Yerlikaya,Azmi; Altıkat,Sayit; Irmak,Reyhan; Cavga,Fatma  Zehra; Kocacan,Sultan  Aysun; Boyaci,Ihsan

doi:10.3892/mmr.2013.1466

Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells

Authors:
- Azmi Yerlikaya
- Sayit Altıkat
- Reyhan Irmak
- Fatma Zehra Cavga
- Sultan Aysun Kocacan
- Ihsan Boyaci
View Affiliations

Affiliations: Department of Medical Biology, Faculty of Medicine, Dumlupınar University, Kütahya 43100, Turkey, Department of Biochemistry, Faculty of Medicine, Dumlupınar University, Kütahya 43100, Turkey, Department of Biology, Dumlupınar University, Kütahya 43100, Turkey, Kütahya Evliya Çelebi Education and Research Hospital, Department of Radiation Oncology, Dumlupınar University, Kütahya 43100, Turkey, İstanbul Medipol University, Vatan Clinic, İstanbul, 34214, Turkey
Published online on: May 8, 2013 https://doi.org/10.3892/mmr.2013.1466
Pages: 277-281

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approved for the treatment of patients with relapsed and refractory multiple myeloma. A number of studies have been conducted to evaluate the activity and safety of bortezomib either alone or in combination with several cytotoxic agents and radiation. In the current study, the efficacy of bortezomib alone or in combination with cisplatin and 5‑fluorouracil was evaluated in 4T1 breast cancer cells, a highly metastatic murine cancer cell line. Using MTT assay, IC50 values of cisplatin and 5‑fluorouracil were determined to be 14.2 and 8.9 µM for cisplatin and 5‑fluorouracil, respectively. The effects of different concentrations of cisplatin and 5‑fluorouracil in combination with two different concentrations of bortezomib were examined in the 4T1 cells. Statistically significant differences were found when 1 or 5 µM cisplatin was combined with 10 or 50 nM bortezomib. Similarly, 1 µM 5‑fluorouracil or 5 µM 5‑fluorouracil in combination with 10 nM bortezomib caused significant cell death as compared to treatment with single agents. However, 1 or 5 µM 5‑fluorouracil did not potentiate the effects of higher concentrations of bortezomib (50 nM). The effect of the combination of cisplatin, 5‑fluorouracil and bortezomib was determined by soft agar assay. It was confirmed that a combination of cisplatin and bortezomib was more effective than each drug as a monotherapy. Therefore, the combination of cisplatin and bortezomib should be tested further in clinical settings.

View Figures

View References

1	Burger AM and Seth AK: The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer. 40:2217–2229. 2004. View Article : Google Scholar : PubMed/NCBI
2	Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI
3	Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R and Puisieux A: Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer. 7:502008. View Article : Google Scholar : PubMed/NCBI
4	Pei XY, Dai Y and Grant S: The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia. 17:2036–2045. 2003. View Article : Google Scholar
5	Yerlikaya A and Erin N: Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int J Mol Med. 22:817–823. 2008.PubMed/NCBI
6	Boccadoro M, Morgan G and Cavenagh J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 5:182005. View Article : Google Scholar : PubMed/NCBI
7	Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P and Van Waes C: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 7:1419–1428. 2001.PubMed/NCBI
8	LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62:4996–5000. 2002.PubMed/NCBI
9	Denlinger CE, Rundall BK and Jones DR: Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg. 128:740–748. 2004. View Article : Google Scholar
10	Teicher BA, Ara G, Herbst R, Palombella VJ and Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 5:2638–2645. 1999.PubMed/NCBI
11	Freshney RI: Cytotoxicity. Culture of animal cells: a manual of basic techniques. 5th edition. Wiley-Liss; New Jersey, NJ: pp. 359–374. 2005
12	Chua BT, Lim SJ, Tham SC, Poh WJ and Ullrich A: Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells. Mol Oncol. 4:323–334. 2010. View Article : Google Scholar : PubMed/NCBI
13	Yerlikaya A, Okur E and Ulukaya E: The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour Biol. 33:1385–1392. 2012. View Article : Google Scholar : PubMed/NCBI
14	Basma H, El-Refaey H, Sgagias MK, Cowan KH, Luo X and Cheng PW: BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. J Biomed Sci. 12:999–1011. 2005. View Article : Google Scholar : PubMed/NCBI
15	Hernandez-Vargas H, Ballestar E, Carmona-Saez P, von Kobbe C, Banon-Rodriguez I, Esteller M, Moreno-Bueno G and Palacios J: Transcriptional profiling of MCF7 breast cancer cells in response to 5-fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer. 119:1164–1175. 2006. View Article : Google Scholar : PubMed/NCBI
16	Plano D, Baquedano Y, Ibanez E, Jimenez I, Palop JA, Spallholz JE and Sanmartin C: Antioxidant-prooxidant properties of a new organoselenium compound library. Molecules. 15:7292–7312. 2010. View Article : Google Scholar : PubMed/NCBI
17	Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D and Neckers L: Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther. 3:551–566. 2004.